CPT® Code 81448

Hereditary peripheral neuropathies (eg, Charcot-Marie-Tooth, spastic paraplegia), genomic sequence analysis panel, must include sequencing of at least 5 peripheral neuropathy-related genes (eg, BSCL2, GJB1, MFN2, MPZ, REEP1, SPAST, SPG11, SPTLC1)

The CPT® Code 81448 pertains to a genomic sequence analysis panel specifically designed for hereditary peripheral neuropathies, which include conditions such as Charcot-Marie-Tooth disease and spastic paraplegia. This analysis involves the sequencing of at least five genes that are known to be associated with these neuropathies, including but not limited to BSCL2, GJB1, MFN2, MPZ, REEP1, SPAST, SPG11, and SPTLC1. Hereditary peripheral neuropathies represent the most frequently inherited neuromuscular disorders, categorized into two main types: primary axonopathies, which affect the axon of the nerve, and primary myelinopathies, which impact the myelin sheath surrounding the nerve fibers. Further classification of these neuropathies can be made based on the type of nerve fibers involved, distinguishing between sensory and motor fibers, as well as large and small nerve fibers. The distribution of the affected nerves can also be characterized by symmetry and length dependency. Symptoms associated with these conditions can vary widely, including progressive distal muscle weakness, paresthesia, loss of sensation, foot drop, and decreased deep tendon reflexes. In cases where only motor nerves are affected, symptoms may include muscle weakness and atrophy, absent reflexes, and foot deformities. Sensory and autonomic neuropathies can lead to a range of symptoms such as diminished sensation, excessive sweating, and gastrointestinal issues. The genomic analysis provided by this test is crucial for establishing a genetic basis for the observed symptoms, confirming inheritance patterns, identifying at-risk pregnancies, and facilitating accurate genetic counseling and family planning. The testing process involves obtaining a blood sample, which is then analyzed using Next Generation Sequencing (NGS) techniques, with subsequent confirmation through Sanger Sequencing to detect any mutations present.